SABS · SAB Biotherapeutics, Inc.

Sab Biotherapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Focused On Developing Multi-Specific, High-Potency, Human Immunoglobulin G (Higg) To Treat And Prevent Immune And Autoimmune Disorders. The Company'S Lead Product Candidate, Sab-142, Targets Autoimmune Type 1 Diabetes (T1d) With A Disease-Modifying Therapeutic Approach That Aims To Change The T1d Treatment Paradigm By Delaying Onset And Potentially Preventing Disease Progression Of Stage 3 T1d Patients. It Is Focused On Developing Product Candidates For Disease Targets Where A Differentiated Approach Has The Greatest Potential To Be Either First-In-Class Against Novel Targets Against Complex Targets To Treat Diseases, Including Type 1 Diabetes (T1d) And Other Autoimmune Disorders.